For Patients: Clinical Trials


INOVIO is committed to developing new, innovative DNA medicines to treat diseases with urgent global health needs including cancer and infectious diseases.
INOVIO currently has the following clinical trials enrolling. For questions or more information please email

DiseaseBRCA1/2 Mutation Carriers
(More Information)
ProgramINO-5401 Study PhasePhase 1 SummaryThe research study is being conducted to test an experimental vaccine to potentially prevent cancer for people with BRCA1 or BRCA2 mutations. This study will test if the vaccine is safe (without significant side effects) and test a new way of administering vaccines. It will also test whether the vaccine activates your immune system.
DiseaseHIV-Positive Anal High-Grade Squamous Intraepithelial Lesions (HSIL)
(More Information)
ProgramVGX-3100 Study PhasePhase 2 SummaryThis Phase 2 trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Electroporation helps pores in your body's cells take in the drug to strengthen your immune system's response. Giving VGX-3100 and electroporation together may work better in treating patients with high-grade anal lesions.
(More Information)
ProgramdMAb-1 and dMAb-2 Study PhasePhase 1 SummaryThis is a Phase 1, open-label, single center, dose escalation study to evaluate the safety and pharmacokinetic profile of mAb-1 and mAb-2 following delivery of optimized dMAb-1 and dMAb-2 with Hylenex® recombinant, administered by intramuscular injection (IM) followed immediately by electroporation (EP) device, in a 2-dose regimen (Days 0 and 3) in healthy adults. The hypothesis is that the administration of dMAb-1 and dMAb-2 will be safe and associated with expression of mAb-1 and mAb-2 in serum.
DiseaseMetastatic Castration-resistant Prostate Cancer
(More Information)
ProgramINO-5151 Study PhasePhase 1/2 SummaryThis study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in participants with mCRPC who have received prior secondary androgen receptor signaling inhibitor therapy (eg, abiraterone, enzalutamide, apalutamide).
DiseaseMiddle East Respiratory Syndrome Coronavirus (MERS-CoV)
(More Information)
ProgramINO-4700 Study PhasePhase 2 SummaryThe purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA™ 2000 device in healthy adult volunteers for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. This study is divided into 2 parts: Part 1- dose finding stage and Part 2- dose expansion stage.